{"id":"tp-61720","type":"article-newspaper","title":"Bausch + Lomb's BL1332 Misses Primary Goal in Phase 2 Eye Pain Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/61720","datePublished":"2026-11-19T22:31:44.000Z","dateModified":"2026-11-19T22:31:44.000Z","language":"en","abstract":"At 24 hours, the topical drug for pain after eye surgery showed no statistically significant improvement over vehicle, an inactive comparison formulation.","section":"Business","references":[]}